Stem’s main risk is not that the product is imaginary; it is that the company may not have enough financial flexibility to let a real software-and-services improvement show through. Liquidity,
backlog conversion, and pricing durability matter more than raw market size. If management misses on cash generation or uses equity defensively, shareholders can lose much of the benefit of an otherwise decent operating turnaround.